Uncategorized Archives - Drugs in Context

Drugs in Context Editorial: Review of 2020 and what lies ahead in therapeutic interventions

Sarah L Anderson, Matteo Bassetti, Arduino A Mangoni

Article Type

Editorial

Published

22 Jan 2021

The Senior Editors of Drugs in Context provide us with their expert opinion on the events of 2020 and what lies ahead in 2021.

Motion sickness: an overview

Alexander KC Leung MBBS, FRCPC, FRCP (UK and Irel), FRCPCH, FAAP, Kam Lun Hon MD, FAAP, FCCM

Article Type

Review

Published

13 Dec 2019

This literature review provides an update on the current understanding of the pathophysiology and management of motion sickness.

Relative bioavailability of three formulations of galunisertib administered as monotherapy in patients with advanced or metastatic cancer

Ivelina Gueorguieva, Ann Cleverly, Durisala Desaiah, Analia Azaro, Joan Seoane, Irene Braña, Elisabet Sicart, Colin Miles, Michael M Lahn, Malcolm I Mitchell, Jordi Rodon

Article Type

Original Research

Published

02 Dec 2016

In this relative bioavailability study comparing galunisertib formulations after a single dose, RCD and RCS formulations had similar exposure and safety profile compared with the HSWG formulation.